Alkermes to present phase 2 Vibrance-1 data on Alixorexton in narcolepsy type 1 at World Sleep 2025
Alkermes announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place… read more.
